Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

Alberto Moreno; Kelly Manning; Maryam I Azeem; Ajay K Nooka; Madison Ellis; Renee Julia Manalo; Jeffrey M Switchenko; Bushra Wali; Jonathan L Kaufman; Craig C Hofmeister; Nisha S Joseph; Sagar Lonial; Kavita M Dhodapkar; Madhav V Dhodapkar; Mehul S Suthar

doi:10.21203/rs.3.rs-3293339/v1

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

Res Sq [Preprint]. 2023 Sep 21:rs.3.rs-3293339. doi: 10.21203/rs.3.rs-3293339/v1.

Authors

Alberto Moreno^{1

2

3}, Kelly Manning^{1

2}, Maryam I Azeem^{4

5}, Ajay K Nooka^{4

6}, Madison Ellis^{1

2}, Renee Julia Manalo⁴, Jeffrey M Switchenko⁶, Bushra Wali^{1

2}, Jonathan L Kaufman^{4

6}, Craig C Hofmeister^{4

6}, Nisha S Joseph^{4

6}, Sagar Lonial^{4

6}, Kavita M Dhodapkar^{5

6}, Madhav V Dhodapkar^{4

6}, Mehul S Suthar^{1

2

7}

Affiliations

¹ Emory Vaccine Center, Emory University, Atlanta, GA.
² Emory National Primate Research Center, Atlanta, GA.
³ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
⁴ Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.
⁵ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA.
⁶ Winship Cancer Institute, Atlanta, GA.
⁷ Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.

Abstract

We characterized virus-neutralization and spike-binding antibody profiles in myeloma patients following monovalent or bivalent-SARS-CoV-2 booster vaccination. Vaccination improves the breadth of binding antibodies but not neutralization activity against current variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

Publication types

Preprint

Abstract

Publication types

Grants and funding